-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 25 news, Zejing Pharmaceutical announced that the company intends to raise 2.
863 billion yuan to promote new drug research and development projects, the third phase of the new drug research and development and production center construction project and supplement working capital
.
According to the data, Zejing Pharmaceutical is an innovation-driven chemical and biological new drug research and development and production enterprise focusing on multiple therapeutic fields such as tumors, bleeding and blood diseases, liver and gallbladder diseases, and immune inflammatory diseases
.
As of the announcement date of this plan, the company has completed 16 new drug research projects, 61 IND (Clinical Trial Approval)/NDA (New Drug Application) declarations, 96 invention patents, and 199 invention patents
.
Among the product lines under research, Donafenib tosylate tablets have been approved for the first-line treatment of advanced liver cancer; there are also 42 research projects of 16 main research drugs, of which 7 indications of 4 drugs are under research.
NDA or Phase III clinical trials, 3 drugs under development are in phase I or II clinical trials, 2 drugs under research have submitted IND applications, and 7 drugs under research are in preclinical research and development; subsidiary GENSUN is committed to discovery and Develop bispecific and trispecific tumor therapeutic antibodies.
The product line includes more than 10 research projects
.
In this fundraising project, approximately 1.
832 billion yuan will be invested in new drug research and development
.
The company stated that it plans to further advance the research and development process of new drugs such as Jacketinib hydrochloride tablets, ZG19018 tablets, ZG005 powder injection, ZG170607 injection, ZG006 powder injection and GS11 powder injection, as well as global simultaneous development, expand the company’s product pipeline, and further enhance the company’s product pipeline.
Differentiated competitive advantage
.
It is reported that if this round of fixed fundraising is successfully implemented, it will help to speed up the company’s marketed product Donafenib tosylate tablets, another blockbuster product Jacketinib hydrochloride tablets for new indications for moderate to severe atopic dermatitis and severe atopic dermatitis.
The clinical registration of ankylosing spondylitis in China further expands the company’s competitive advantage in the field of JAK inhibitors
.
In addition, this round of fixed increase plans to invest 726 million yuan in the third-phase construction project of the new drug R&D and production center.
The second-phase construction project of its new drug R&D and production center is under construction.
The company intends to further optimize the R&D and production center on this basis.
Construction, further expand the area of the pilot plant for biological drug research and development, and increase the research and development of innovative drugs to lay the foundation for the company’s new drug reserves; at the same time, the company plans to further construct and optimize new drug production facilities to encourage external recombinant human thrombin to expand its production scale , In order to meet the rapid growth of domestic and international market demand, and lay a good foundation for the commercialization of subsequent products
.
Judging from financial data, the company is not yet profitable
.
From 2016 to 2020, Zejing Pharmaceutical lost 128 million yuan, 146 million yuan, 440 million yuan, 462 million yuan, and 319 million yuan respectively
.
In this regard, Zejing Pharmaceutical has explained that the company is a biomedical company listed on the sci-tech innovation board's fifth set of listing standards.
The company's products, except for the first-line treatment of advanced liver cancer, were approved in June 2021, except for Donafenib tosylate tablets.
Outside of the listing, other products are still in the R&D stage, with relatively large R&D expenditures, and have not yet achieved profitability
.
From January to September this year, Zejing Pharmaceutical's net profit loss was nearly 300 million yuan, a year-on-year decrease of about 28%, and the chain loss was also further expanded
.
In this regard, the company pointed out that Donafenib tablets have been on the market for a short time, and still need to continue to invest more in the initial market expansion and academic promotion activities, and other products are still in the research and development stage, and the research and development expenditure is relatively large, so the company is not profitable and exists.
Accumulated uncovered losses
.
863 billion yuan to promote new drug research and development projects, the third phase of the new drug research and development and production center construction project and supplement working capital
.
According to the data, Zejing Pharmaceutical is an innovation-driven chemical and biological new drug research and development and production enterprise focusing on multiple therapeutic fields such as tumors, bleeding and blood diseases, liver and gallbladder diseases, and immune inflammatory diseases
.
As of the announcement date of this plan, the company has completed 16 new drug research projects, 61 IND (Clinical Trial Approval)/NDA (New Drug Application) declarations, 96 invention patents, and 199 invention patents
.
Among the product lines under research, Donafenib tosylate tablets have been approved for the first-line treatment of advanced liver cancer; there are also 42 research projects of 16 main research drugs, of which 7 indications of 4 drugs are under research.
NDA or Phase III clinical trials, 3 drugs under development are in phase I or II clinical trials, 2 drugs under research have submitted IND applications, and 7 drugs under research are in preclinical research and development; subsidiary GENSUN is committed to discovery and Develop bispecific and trispecific tumor therapeutic antibodies.
The product line includes more than 10 research projects
.
In this fundraising project, approximately 1.
832 billion yuan will be invested in new drug research and development
.
The company stated that it plans to further advance the research and development process of new drugs such as Jacketinib hydrochloride tablets, ZG19018 tablets, ZG005 powder injection, ZG170607 injection, ZG006 powder injection and GS11 powder injection, as well as global simultaneous development, expand the company’s product pipeline, and further enhance the company’s product pipeline.
Differentiated competitive advantage
.
It is reported that if this round of fixed fundraising is successfully implemented, it will help to speed up the company’s marketed product Donafenib tosylate tablets, another blockbuster product Jacketinib hydrochloride tablets for new indications for moderate to severe atopic dermatitis and severe atopic dermatitis.
The clinical registration of ankylosing spondylitis in China further expands the company’s competitive advantage in the field of JAK inhibitors
.
In addition, this round of fixed increase plans to invest 726 million yuan in the third-phase construction project of the new drug R&D and production center.
The second-phase construction project of its new drug R&D and production center is under construction.
The company intends to further optimize the R&D and production center on this basis.
Construction, further expand the area of the pilot plant for biological drug research and development, and increase the research and development of innovative drugs to lay the foundation for the company’s new drug reserves; at the same time, the company plans to further construct and optimize new drug production facilities to encourage external recombinant human thrombin to expand its production scale , In order to meet the rapid growth of domestic and international market demand, and lay a good foundation for the commercialization of subsequent products
.
Judging from financial data, the company is not yet profitable
.
From 2016 to 2020, Zejing Pharmaceutical lost 128 million yuan, 146 million yuan, 440 million yuan, 462 million yuan, and 319 million yuan respectively
.
In this regard, Zejing Pharmaceutical has explained that the company is a biomedical company listed on the sci-tech innovation board's fifth set of listing standards.
The company's products, except for the first-line treatment of advanced liver cancer, were approved in June 2021, except for Donafenib tosylate tablets.
Outside of the listing, other products are still in the R&D stage, with relatively large R&D expenditures, and have not yet achieved profitability
.
From January to September this year, Zejing Pharmaceutical's net profit loss was nearly 300 million yuan, a year-on-year decrease of about 28%, and the chain loss was also further expanded
.
In this regard, the company pointed out that Donafenib tablets have been on the market for a short time, and still need to continue to invest more in the initial market expansion and academic promotion activities, and other products are still in the research and development stage, and the research and development expenditure is relatively large, so the company is not profitable and exists.
Accumulated uncovered losses
.
